主动式与被动式经皮骨导助听装置的系统评价与荟萃分析
主动式装置功能听力改善31.8 dB,高频增益优于被动式,但证据质量整体偏低,缺乏高质量对照研究。
要点
- 主动式tBCHD功能听力改善31.8 dB(95%CI 27.7-35.9),被动式改善范围25.2-44.3 dB。
- 主动式高频增益优于被动式,2、3、4、6 kHz加权平均增益分别为26.5、25.7、31.8、34.3 dB。
- 两类装置均改善交流便利性、混响及背景噪声下言语可懂度,安全性可接受。
核心结论
- 主动式和被动式tBCHD均具有可接受的安全性并改善生活质量。
- 主动式装置可能提供更好的听力结局,尤其在高频,但缺乏高质量对照研究。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、EMBASE、CINAHL和Cochrane CENTRAL自建库至2019年9月23日。
- 采用随机效应模型进行荟萃分析,使用Newcastle-Ottawa量表和病例系列质量评价工具评估偏倚风险和质量。
主要发现
- 主动式装置汇总并发症发生率为14.8%(95%CI 0.09-0.21,I2=0%)。
- 主动式装置在混合性或传导性听力损失者中功能听力改善31.8 dB(95%CI 27.7-35.9,I2=44.6%)。
- 被动式装置功能听力改善范围为25.2至44.3 dB。
- 主动式装置2、3、4、6 kHz加权平均听力增益分别为26.5、25.7、31.8、34.3 dB,被动式分别为26.2、21.1、16.8、6.4 dB。
- 两类装置均改善交流便利性、混响及背景噪声下言语可懂度。
临床怎么用
- 临床选择tBCHD时可考虑主动式装置在高频听力增益方面的潜在优势。
- 需结合患者听力损失类型、高频需求及并发症风险个体化选择主动或被动装置。
局限性
- 纳入研究总体质量偏低。
- 缺乏高质量对比研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Active and passive transcutaneous devices (tBCHDs) have been introduced in an effort to address complication concerns with percutaneous devices. Direct comparison of active and passive devices through evidence synthesis practices is incomplete. This systematic review and meta-analysis sought to synthesize and compare available evidence on audiological, quality of life, and complication-related outcomes of active and passive tBCHDs. DESIGN: MEDLINE, EMBASE, CINAHL, and Cochrane CENTRAL were searched from inception to September 23, 2019. Observational and experimental studies investigating active or passive tBCHDs in adults were eligible. Studies were screened independently in duplicate. This study is reported in accordance with the PRISMA guidelines. Risk of bias and quality assessments were completed using the Newcastle-Ottawa Scale and the Quality Appraisal Tool for Case Series. Meta-analysis was performed with random-effects models. Audiological outcomes included changes in pure-tone average, functional hearing, and high-frequency hearing. Quality of life outcomes included patient-reported results. Complications included minor, major, and total complications experienced. RESULTS: One thousand five hundred forty-two nonduplicate articles were screened. Twenty-eight studies were included. Quality of included studies was low overall. The pooled complication rate for active devices was 14.8% (95% confidence interval: 0.09-0.21, I2: 0%). The pooled improvement in functional hearing for active devices among those with mixed or conductive hearing loss was 31.8 dB (95% confidence interval: 27.7-35.9, I2: 44.6). Improvement in functional hearing ranged from 25.2 to 44.3 dB for passive devices. Active devices provided improved high-frequency hearing compared to passive devices: the weighted average hearing gains at 2, 3, 4, and 6 kHz were 26.5, 25.7, 31.8, and 34.3 dB for active devices and 26.2, 21.1, 16.8, and 6.4 dB for passive devices, respectively. Both device types demonstrated improvement in ease of communication, reverberation, and understandability in background noise. CONCLUSIONS: Both active and passive tBCHDs demonstrate acceptable safety profiles and QoL improvements. Active devices may provide better hearing outcomes, especially in high frequencies, but high-quality comparative studies are lacking. Future work is needed in this regard.
引用
- Forner D, Noel CW, Horwich P, et al. Active Versus Passive Transcutaneous Bone Conduction Hearing Devices: A Systematic Review and Meta-Analysis. Ear Hear. 2022. PMID: 34191755. doi:10.1097/AUD.0000000000001088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。